result
februari busi month result five compani coverag
report convatec result better expect recoveri
suppli issu advanc wound ostomi franchis on-going
indivior miss forecast slightli view guidanc realist
sublocad launch track
initi two new stock focu antibodi technolog molecular
partner morphosi like molecular partner darpin technolog
bullish lead asset abicipar age-rel macular degener
morphosi think key pipelin event factor
current share price see long-term valu antibodi technolog
north american colleagu note number read-across topic
coverag roch competitor asset moln abicipar
ii morphosi peer present promis result moder sever
atop dermat iii report strong sale tremfya iv car-t
repres threat antibodi oncolog despit slow initi uptak
host annual healthcar confer new york
attende eu coverag host follow compani clin hmed
moln sph sann remain posit hmed moln
compani set report data lead asset kidney transplant
abicipar wamd respect confid match manag
view follow-on pipelin asset think fair say
equiti stori compani still well known us today
takeaway find document
takeaway month page
eu research valuat tabl page
month ahead trade idea page
versu consensu upcom result page
newsflow north america page
price market close gmt march
takeaway month eu healthcar research
februari busi month result dechra clinigen report interim
result hansa medic convatec indivior hansa medic note
strong cash posit focu remain readout highd
investigator-l trial expect convatec result better
expect recoveri suppli issu awc ostomi franchis
on-going indivior miss forecast slightli ep line view
guidanc realist sublocad launch track
dechra interim show strong set number driven perform us
posit impact ep line us tax reform think strong
perform phase relat see share near fair valu clinigen
ebitda line forecast ep ahead due effici cost control
lower tax saw neg share price reaction thereaft reiter
long-term thesi focus underli growth driver unlicens
commerci medicin busi
initi two new stock focu antibodi technolog molecular
partner morphosi like molecular partner darpin technolog
bullish lead asset abicipar age-rel macular degener
morphosi see valu pipelin asset technolog platform think key
pipelin event factor current share price
regulatori level shield therapeut report neg top-lin result
us pivot phase trial patient iron defici anaemia chronic
kidney diseas ckd whilst drug safe well toler primari
endpoint demonstr chang haemoglobin baselin compar
placebo week met shield process evalu next step
host follow compani year healthcar confer new
york clin hmed moln sph sann udg remain posit hmed
moln compani set report data lead asset kidney
transplant abicipar wamd respect confid match
manag view follow-on pipelin asset think fair
say equiti stori compani still well known us today
hansa specif learn new insight develop pathway
kt strategi wider solid organ transplant space provid us
confid manag aim enhanc valu asset
reach market time manner possibl firesid chat
clinigen manag outlin key driver compani continu
see long-term organ growth compani aim distributor choic
territori outsid us perhap build upon market-
lead posit within earli access market whilst bolt-on product also
udg gave slick well-rehears present compani outlin
posit within pharma outsourc market commercialis packag
strong balanc sheet accentu organ growth potenti lastli
sinclair manag firesid chat day compani announc
end us distribut agreement thermi almiral end-march whilst
manag obvious frustrat thing progress us
opportun still compani captur think decis
action taken well investor separ think opportun eu
brazil china mean compani well posit grow revenu
profit regardless us issu
highlight eu healthcar research
molecular partner eye prize initi outperform spec risk
initi coverag molecular partner swiss clinic stage biotech compani
outperform specul risk rate found spin-off univers
zurich compani develop antibody-lik protein therapeut call darpin
use oncolog ophthalmolog darpin base ankyrin motif one
common protein bind motif present speci engin
specif target multi-step process
lead asset abicipar mono-darpin target vegf well-characteris target
ophthalmolog pivot phase studi age-rel macular degener
read-out expect bullish posit data previou studi
suggest signific advantag abicipar soc favour longer-dos
interv asset outlicens allergan estim launch peak
sale see mileston royalti
abicipar mileston royalti
dme indic
santhera pharmaceut highlight healthcar confer
healthcar confer februari host thoma meir ceo
firesid chat break-out session takeaway
includ healthcar confer report follow
santhera pharmaceut recap swiss specialti pharma focus three therapeut
area rare neuromuscular neuro ophthalmolog cystic fibrosi one asset
ii raxon idebenon alreadi approv eu leber hereditari optic neuropathi
lhon rare inherit form blind iii current develop
idebenon develop dmd idebenon small molecul facilit
product energi mitochondri level mitochondri enhanc
biolog rational use dmd sinc one downstream consequ
dystrophin defici uncontrol influx calcium mis-product energi
cell lack atp ultim contribut patholog diseas
idebenon develop dmd includ complet studi delo posit
data dmd patient treat steroid on-going studi sidero
dmd patient treat steroid centr largest dmd studi conduct
far follow patient year data expect
sann continu develop idebenon plan us file eu
dmd patient treat steroid idebenon compound
posit data dmd yet despit chmp adopt neg opinion initi
submiss sep re-examin appeal jan dr meir
compani present aacr-nci-eortc intern confer molecular target
comment chmp fill idebenon type variat ad anoth
indic exist approv lhon requir robust evid efficaci
equival full approv henc although data posit
patient singl posit studi fulfil requir full
approv sidero trial due read-out end howev
compani plan submit fda condit approv data
delo studi non-steroid treat dmd patient addit plan re-
appli file ema idebenon non-steroid treat dmd
stand-alone indic henc qualifi consider condit approv
step refil eu idebenon dmd ema refil sann need
gener addit data accord chmp feedback need run
anoth placebo control trial like scenario compani run
small biomechan studi link effect drug muscl tissu respiratori
function outcom timelin final yet accord dr meir
compani discuss expert field collect data
manag hope time next year prepar new submiss also
learn regul would like see data idebenon delay time
assist ventil surrog mortal thu sann submiss
dossier ema intend initi open label extens ole
trial idebenon treat patient follow five year
primari endpoint time assist ventil result ole trial
compar natur histori data alreadi exist use
support sann submiss packag ema
eu regulatori hurdl clinic relev respiratori function declin endpoint
ii recogn dmd patient popul treat steroid
resolv accord dr meir regul familiar respiratori
function declin endpoint acknowledg clinic valid
endpoint problem deriv respiratori function loss airway
infect older patient becom wheelchair bound ii sann
compani focus older patient use steroid dmd patient treat
steroid start year high dose steroid also associ side
effect eventu caus patient stop typic time becom
wheelchair depend henc two dmd popul younger popul
ambulatori use steroid older popul non-ambulatori typic use
steroid eu regul recogn patient use steroid
clinic defin popul deserv treatment
idebenon could effect also patient use steroid natur histori data
shown patient use steroid eventu experi declin
respiratori function use steroid delay declin year
posit effect steroid lost rate declin patient
take steroid studi sidero trial look patient steroid
idebenon replac steroid therapeut current avail
indic younger patient due cours diseas
point benefit risk balanc steroid use longer posit due
side effect idebenon compet steroid offer treatment
steroid fail dr meir comment last month seen
data public suggest correl steroid use
respiratori declin three independ public demonstr steroid
benefici delay respiratori declin respiratori function start declin
patient stop benefit steroid
clinigen keep calm carri
reiter long-term thesi clinigen follow analyst present
address clinigen share price reaction interim result feb see note
think share price fall akin profit warn perceiv
worst mix set result setback
would point lowest proport group gross profit
lowest qualiti given low barrier entri henc focu long-term
thesi opportun unlicens commerci medicin busi
unlicens busi managed/earli access unlicens drug distribut
see three main growth driver busi focu non-cor market leverag
clinigen expertis infrastructur on-line access custom
cliniport platform convert manag access program global distribut
licens leverag clinigen posit largest manag access player see
hospit survey note commerci medicin highlight underli growth
potenti upsid qp pipelin option bolt-on
product acquisit think point strength off-set under-perform
divis see new incom manag move turnaround
exhibit pleas list top three compassion use manag earli access supplier order frequenc use list
rank order popular
dph ln dutch deal addit share price event
dechra made anoth two strateg sound acquisit ast farma let vet
beheer group independ develop companion anim equin gener
pharmaceut base netherland essenti bring in-hous suit
product low oper integr risk see ep accret
estim howev whilst scope bolt-on deal revenu
upsid pipelin think much captur current share price
henc move outperform sector perform
hzd ln trade updat line low-end expect question like
ask
trade statement overal see updat neutral neg think
test investor patienc yet initi take consensu downgrad
like forecast year toward low-end expect ebitda
profit push back guidanc continu progress
profit alreadi assum consensu expect
ebitda posit think realist
expect time
indv ln tax tax
indivior issu better-than-expect tax guidanc see like
consensu ep upgrad prior tax guidanc come base current
read new law lower us feder corpor incom tax rate
along indivior exist tax posit compani expect high-teen
effect tax rate forese futur alreadi lower
tax rate tri captur benefit line benefit seen
uk list peer read us like possibl lead
ep upgrad els equal origin tax guid level
stx ln phase failur ckd
neg news morn compani report neg top-lin result
us pivot phase patient iron defici anaemia chronic kidney
diseas ckd shield lead asset feraccru fail demonstr statist differ
chang haemoglobin baselin compar placebo week
g/dl primari endpoint compani better understand
reason failur potenti reassess us develop
strategi unlik help share like neg impact
news outcom clearli unexpect given qualiti
data seen prior studi particularli ibd neg invest thesi
focus us market valu drug approv
sandoz receiv anoth delay gener advair space
note articl reuter fda issu complet respons letter
sandoz gener advair program updat follow problem seen
peer hikma/vectura latter re-fil applic fda
novemb mid-jun action date detail
sandoz think anoth player gener space receiv highlight
complex underli process would surpris see
delay announc provid mid-jun action date posit
would first launch peer delay would see
posit consort next expect hear vectura outcom disput
resolut fda
hmed ss result surpris eye clinic data
hansa result show real surpris focu remain clinic trial
programm lead asset kidney transplant anticip updat
key studi continu believ hansa igg-cleav technolog
unlock valu beyond kt initi indic
moln sw eye prize initi outperform spec risk
molecular partner clinical-stag biotech differenti believ
lead technolog deliv antibody-lik product multipl benefit
convent platform see upcom data point significantli de-risk
platform lead valuat inflect point ahead investor buy
initi outperform specul risk sotp-deriv pt
mor gr price success littl risk initi under-perform
see valu mor technolog pipelin potenti signific long-
term upsid howev evalu major partner proprietari asset
factor potenti posit catalyst clinic stage success mani case see
key pipelin event perhap even captur current
share price initi under-perform
indv ln healthi guid doj fear persist
result miss ep expect guid posit
line estim meaning ahead consensu potenti consensu
upgrad elsewher think investor sentiment could focu higher doj
provis compani afford new news
gener litig whilst sublocad launch track feb
ctec ln result better expect patienc requir
convatec result better consensu expect think
share price reaction time write appear factor belief
turnaround perhap guidanc suggest howev balanc
guidanc consensu expect recent news peer think
investor stay cautiou see guidanc realist
mor gr updat neg read-across morphosi partner asset
yesterday announc blind examin on-going
alzheim studi aducanumab adu expand number patient
due variabl seen primari endpoint cdr-sb order
maintain power see news aducanumab provid neg read-
across morphosi partner asset roch gantanerumab gant
modestli increas develop risk support view high
biolog risk indic
clin ln highlight healthcar confer
host cfo martin abel firesid chat break-out session saw session
consist current invest thesi base solid organ growth
stori still earli stage see multi-year strategi across number
area particularli tripl region link acquisit recent qp
acquisit combin clear strategi
sph ln us partnership almiral end far alreadi factor
share price
sinclair announc end thermi relationship us key brand
silhouett separ enter convert loan note ew
healthcar partner pay earli exit partnership buy back excess
stock believ formal end partnership unexpect
factor share price extrem weak sinc recent trade
statement sinclair manag elud disappoint partnership
sph ln takeaway healthcar confer
host ceo chri spooner healthcar confer firesid chat
break-out session think deterior share price last
month rais question concern investor forc us re-examin
stanc name multipl time continu believ current share
price materi undervalu busi stand today
dph ln strong phase captur upsid
result finish ahead ebit forecast due oper leverag
ep tax benefit repres solid trade period howev see
benefit phase relat chang ebit ep think
well dechra believ share near fair valu momentum price
estim least
clin ln much ado noth
ebitda line forecast ep ahead thank good cost control
lower tax see currenc shave ep see
revers lower tax focus momentum chang
underli view see investor sentiment improv valuat nudg slightli
yield pt
clin ln keep calm carri
follow analyst present sale desk present reiter
long-term thesi focu unlicens commerci opportun
address share price reaction post interim result februari particular
unlicens busi focu managed/earli access unlicens drug
distribut see three key growth driver focu non-cor market leverag
clinigen expertis infrastructur on-line access custom
cliniport platform convert manag access program global distribut
licens commerci medicin busi would highlight underli
growth upsid qp pipelin option bolt-on
product acquisit think point strength off-set under-perform
divis see new incom manag move turn around
healthcar valuat tabl sector perform chart
price market close march gmt
capit market estim factset price inform
companyrecupsideptpricemcapevforecast growthforecast growthforecast compound-annual-growth-rate compound-annual-growth-rate compound-annual-growth-rate spec spec medic aboutperform spec seknanananananananananananahorizon discoverysector perform spec biopharma outperform spec partnersoutperform spec spec therapeuticsoutperform spec exclud cureti salesev ebitdap eu healthcar
exhibit weight averag share price perform coverag versu ftse share
jan march
jan
jan march
jan march
jan march
jan march
share exhibit coverag perform versu peer wider sector
jan march
jan march
jan march
medicalnmc dechra pharmaceuticalseco anim groupabcamindiviorcv groupudg careianc pharmagenuscaretech holdingsclinigen groupconsort medicalfts sharestoxx europ esmith nephewmorphosysmolecular partnersastrazenecacambian groupglaxosmithklinehorizon discoveri groupbtgshiresinclair pharmaspir care gp vectura groupbenchmark holdingshikma pharmacircassia medicalnmc dechra pharmaceuticalsindiviorabcameco anim groupcaretech holdingsi pharmagenusmorphosyscambian groupudg carehorizon discoveri groupcv groupclinigen groupfts sharesmith nephewstoxx europ eastrazenecaconsort medicalbtgglaxosmithklinemolecular partnersspir care gp shirebenchmark holdingscuretissinclair pharmavectura grouphikma pharmaceuticalscircassia hansa medicaldechra pharmaceuticalsmorphosysabcamcambian groupianc pharmahorizon discoveri groupindiviorclinigen groupcaretech holdingsudg caregenusmereo biopharma groupconsort medicalbtgeco anim groupastrazenecamolecular partnerssmith nephewstoxx europ efts sharecircassia pharm cv groupcuretisconvatec groupglaxosmithklinesinclair pharmashirebenchmark holdingsspir care gp vectura groupsantherahikma pharmavernalisshield month ahead trade idea
look march interim abcam result vectura
interim result look detail trade
perform ii margin develop iii updat move new end-market
 diagnost applic iv potenti
interim trade statement januari abcam announc cer growth
catalogu busi group overal small currenc headwind
move revenu forecast reflect strong underli growth
dynam trade perform think revenu upsid potenti
possibl sinc see abcam well posit benefit key trend
healthcar pharma industri focu biolog research
go result look detail financi post
trade updat earli januari ii updat strateg review iii news
disput resolut process fda
trade updat vectura announc strateg review invest
strategi lead reduct forecast spend
cautiou view vectura next newsflow disput
resolut fda might like neg see clear catalyst
potenti catalyst timet coverag coverag peer
exhibit potenti catalyst timet coverag coverag peer
note indic project result releas date
stockchaprilmayabcam interim result horizon discoveri capit ket day merck kgaa result fisher result apr result may biorad result may tbc biom upadvanc medic solut result ergom result result tbc result apr result apr integra lifesci result apr tbc baxter result tbc result may tbc btgye trade result may result may pharmaceut result medicalhikma result result apr consort ye trade updat tbc aptar result apr recipharm result apr result may advanc medic solut result result apr result may coloplast result may smith nephew result may result may curetisqiagen result may result ch vetoquinol ch result apr result may phibro result may medicalhorizon discoveri merck kgaa result capit ket day result may result result drl gener alvogen court case orexo result apr result may camuru result may biopharmaphas top line result oral aromatas inhibitor develop obes men hypogonad hypogonad apr tbc molecular partnersaudit financi tbc result apr novarti result apr roch result apr result may result ch updat fda file decis novarti result apr gsk result apr roch result apr phase data ra tbc initi phase atop dermat tbc santheratoplin phase data raxon ppm tbc result sarepta result apr result may vifor pharma result ch preliminari result tbc allergan result may outcom disput resolut fda gener advair potenti re-submiss timelin hikma result preliminari result result apr result may preliminari result tbc gsk result apr decis fda unyvero devic result tbc diasorin result potenti feedback fda meet track statu result april tbc
versu consensu upcom result
exhibit versu consensu compani report soon note consensu expect may small number contributor
molecular partner report audit financi march
factset capit market estim
stockmetricconsensu fcst fcst fcst june year pharmavecturamorphosysmolecular partner newsflow item north america
north american colleagu believ key newsflow revolv around
specif compani updat relev eu cover name alongsid
topic budget deal cell therapi cover compani saw
updat galapago roch sarepta therapeut
regeneron pacira see influenc stock uk particular
morphosi molecular partner santhera vectura
potenti walgreen
amazon yet set
disrupt healthcar
medium threat abicipar
georg hill comment wsj articl report earli talk walgreen boot
allianc acquir view high-singl- digit around ep
accret first three year possibl question strateg rational
addit georg hill host panel hospit purchas execut annual
healthcar confer key takeaway panel discuss
whilst amazon appear well suit match hospit buyer on-line supplier
yet necessari infrastructur provid assur product
integr like see low unit measur distribut challeng
kennen mackay detail result roch bispecif
dme data show improv lucenti compel
eylea see read-across molecular partner abicipar note
dose everi week versu abicipar everi week believ role
greater pathophysiolog retin vascular diseas retin
vein occlus diabet macular oedema remind trial eylea
combin nesvacumab fail thu remain
cautiou wait see data chang
assumpt high threat competitor current medium
continu risk pure
also see regeneron issu regard uptick intraocular inflamm ioi
select eylea lot emphasizing/reiter high purif standard requir
ophthalm use biolog ioi remain potenti risk abicipar
irrespect efficaci
promis result
galapagos/morphosi
asset
moder sever atop
high risk uncertainti
clinic develop
post strong sale
tremfya first two
fda guidanc dmd
offer small benefit
american academi dermatolog aad confer brian abraham
kennen mackay comment data atop dermat galapagos/morphosi
respect posit
morphosi fuller set data present highlight alreadi
posit potenti initi data disclos septemb
model asset wait updat progress
evalu subcutan formul ii initi data adjust
upward forecast remind administ weekli
iv formul see indirect read-across competitor
differ mechan action slightli ahead develop potenti
conveni dose schedul kennen report enter
sc dose test continu monitor develop
see matur data asset difficult draw
concret conclus durat respons compar
morphosi partner roch see decis merck discontinu
develop bace inhibitor verubecest highlight high risk
uncertainti asset develop alzheim around valid target and/or
appropri patient popul news give us comfort increas
probabl success partner asset gantenerumab news decreas
assign probabl either sinc although target pathway mechan
action differ
report result accord glenn novarro tremfya launch
steep posit trajectori sale first two quarter seen far posit
morphosi help off-set lost revenu novarti quicker keep
monitor quarterli sale see trend continu
brian abraham see recent fda guidelin develop drug duchenn
muscular dystrophi dmd support use dystrophin express
surrog endpoint potenti acceler approv see read-across sann
upcom fda submiss note santhera idebenon mechan action
downstream dystrophin express henc data would avail
although see posit recent shift polici fda remain skeptic
potenti success acceler approv plan us fill
uptak cellular therapi
slow time
present threat
morphosi molecular
healthcar confer former ceo novarti comment
cellular therapi car-t current challeng caus initi uptak slow
howev next year given efficaci benefit second gener
therapi becom avail move frontlin uptak increas support
assumpt car-t competitor morphosi
molecular partner multi-darpin multipl myeloma
brian abraham comment budget deal came senat
includ provis manufactur pay medicar part increas
amount howev limit impact individu compani
neg vote exparel
fda adcom panel
although previous mention partner product exparel like
meaning financi impact vectura royalti given benefit may
fall outsid vectura set royalti timelin vote adcom panel
asset remov financi benefit complet
exhibit stock cover dougla miehm
titl link note
compel near-term catalyst
potenti treatment lupu
nephriti initi outperform
shire report result bmo februari anticip revenu con ep
con believ product sale guidanc growth rang total
revenu rang continu view valuat compel see limit near-term
catalyst could allow recoveri
initi coverag aurinia outperform specul risk rate price target
compani drug candid voclosporin current ph trial treatment lupu nephriti potenti
becom first fda-approv treatment diseas believ auph attract opportun upsid vs
today valuat next month
larg line better guidanc
mix like conserv ep
revenu vs forecast consensu shire report revenu
vs forecast consensu although top-lin weaker anticip
earn stronger consensu estim guidanc mix
slight beat quarter
mix outlook
shire result line better consensu estim importantli shpg provid
guidanc view mix top line ahead estim ep lower confer call topic
discuss gross margin pressur hemophilia market outlook capit alloc strategi
pli cn mechan action
publish american journal patholog
earlier today promet disclos mechan action publish american journal
patholog view news posit investor wait public time overal
releas confirm earlier commentari act multipl receptor disclos specif target
vrx preview look ahead
glass half-empti half-ful
valeant report result market open februari anticip revenu adj
ebitda adj ep believ focu releas accompani confer call
guidanc specif believ investor look gain clariti impact divestitur recent
launch manag outlook
shire shpg announc pdufa date
earli morn shire announc fda accept bla grant prioriti review lanadelumab
treatment remind investor prioriti review shorten review period target eight month
rather standard twelv month period pdufa date set august
preview focus outlook
note mix reimburs impact
crh report result march market close confer call take place follow morn
estimate dial-in detail believ focu remain payor mix quarter feed
manag outlook follow reimburs chang
 guidanc
expect quarter line
guidanc slightli expect focu like remain loe impact addit full year result valeant
provid guidanc morn compani anticip revenu adj ebitda rang
first glanc view guid conserv look underli assumpt behind
manag outlook notabl believ street focu expect loe impact
exhibit stock cover randal stanicki
titl link note
look earn call pipelin
focu move higher
head less debat greater pipelin focu provid guidanc earli jan
clean much controversi reflect move high jan pull back
believ stock link pipelin updat specif around cgrp ii
esmya expect chang view sever thing look
gener pharma read lupin earli call us
pressur continu lupin see closer bottom
india-bas lupin report fiscal held earli call discuss trend lupin one
larger india pharma/gener compani revenu quarter come north america
sever takeaway follow colour last quarter link
deliv solid guidanc updat
posit oral cgrp data cc
 outlook achiev valuat favour
gener pharma read india-bas natco gx
copaxon partner big focu
learn
report result came consensu revenu billion ep
street billion ep beat driven larg higher gross profit
off-set higher spend major upsid model come tax
line item varianc line item detail result asid expect
focu two thing new guidanc rang previou floor
ii separ announc posit result first two phase trial ubrogep acut
migrain bottom line macro still domin trade action sell-off share late
jan high sharper drg
solid outlook modestli push street number higher deliv wide anticip
ubrogep phase data keep pipelin debat stock bull case point limit pipelin
valu outlook bear case question valu pipelin risk/reward attract
level addit cgrp/esmya updat come next coupl month
listen natco fiscal earn call took place et last night compani
smaller india-bas gener manufactur import cross-read larg gener copaxon
partner detail multi-stock copaxon set-up report publish yesterday
gener copaxon competit deep dive cross-stock analysi competit time say
leav call see four point worth highlight us commentari cross-read ii
learn gener copaxon market iii learn still want colour iv
india-bas call matter next
share volatil stock sit within highs/low last coupl
month head toward feb exparel adcom nerv block indic call volum
high sentiment neg leav view asymmetr set-up stock
upsid clearli linger question like risk/reward long
view three main question ahead nerv block
adcom like risk/reward
titl link note
 fda draft guidanc bring bull/bear
 ema updat keep focu esmya pend
 fda brief doc ahead exparel nerv block
adcom expect without debat
deal take long close ftc hurdl play
broader implic
attend overal tone downbeat
learn
 day exparel adcom panel line
expect surpris yet
fda publish draft guidanc link around studi need develop gener liposom
bupivacain inject exparel weigh stock alreadi weak tape also brought
buy/avoid debat stock high impli volatil meaning upcom catalyst
feb advisori committe hear regard nerv block snda bottom line anytim
guidanc provid around brand drug knee-jerk reaction concern case
report link european medicin agenc ema pharmacovigil risk assess
committe prac current review esmya uterin fibroid europ follow report seriou
liver injuri four case link today ema put press releas recommend temporari
measur liver monitor women take esmya uterin fibroid liver function test least
per month stop treatment liver enzym level upper limit normal
notabl prac also recommend new patient start esmya patient
complet cours treatment start anoth time
earlier afternoon fda releas brief document week advisori committe meet
exparel nerv block feb link meet doc topic discuss broadli
consist expect link efficaci concern broad label safeti featur
fda draft question bottom line none overli surpris stock reaction market
underscor much debat uncertainti go wed/thur view unchang
think outcom go either way littl stock assum nerv block indic
discuss today aam confer investors/execut around freseniu
acquisit take long ii spread wide deal
suppos close immin unclear heard concern around evolv ftc divestitur view
complex product possibl hurdl could broader sector implic
attend annual associ access medicin aam formerli gpha confer
attend notabl offici last year seem lower gener tone
notic subdu put perspect industri enthusiasm seemingli attend
lowest seen close year attend confer indic industri face
structur headwind host investor dinner held privat formal meet hallway
discuss gener execut
industri contact overal start week
hoping/anticip come away construct
advisori committe meet exparel label expans nerv block kick yesterday
afternoon bulk session consist pcrx present follow session
panel follow releas meet brief doc earlier week link overal
whole lot surpris stuck script thought question panel
balanc fair bottom line view remain unchang includ possibl split label
today clearli import session day begin fda present
conclud public hear committe discuss
titl link note
 adcom panel vote nerv block
thought
make stock work continu
explor option unlock valu
gener quick thought hikma
execut announc morn
manag dinner laid strategi nerv block
continu like set-up post manag meet
kpmh set disrupt
apadaz approv focu pbm deal
specialti pharma
focus week
day half advisori committe meet conclud afternoon day link
came surpris today brought signific debat led vote question
alter data submit support approv addit indic nerv block
bottom line outcom hope meet tone frustrat expect
low head adcom think stock larg posit neg outcom
share continu challeng recur question hear make stock
work manag effect shore expect institut cost-restructur
program address loe impactboth posit move look question heard
investor around addit action address weak maintain outperform continu
see sotp valu
two c-suit announc within global gener morn sector perform
hikma cover receiv question around thought move want add
context
host dinner prior present healthcar confer tomorrow
morn dinner discuss surprisingli focus nerv block follow last week
neg adcom decis pdufa well core underli busi partnership
stock move meaning lower nerv block disappoint expect
pdufa apadaz fri anticip approv also see potenti uniqu pbm deal
struck shortli thereaft could bring surpris opioid market could add valu
attract upsid come set read phase mid-year reiter op
see kmph larg radar
kmph share fri late day apadaz approv approv posit expect
announc potenti pbm/distribut deal serv next catalyst apadaz
add valid still think materi valu driver kmph platform come
phase data mid-year rais price target model updat reiter op
leav busi week back healthcar confer day day recap head
busiest week earn quarter sever compani expect give first-tim
guidanc among other incom call pick post
note call new ftc polici hurdl deal close link two addit sell-sid shop
publish past week follow wsj articl dig new polici ftc deal
make got tougher struggl gener drugmak februari spread
freseniu cover report et like report via on/around
titl link note
bring littl surpris focu remain
pipelin cc et
sever import data read
dictat stock path
deal concern materi higher
freseniu investig alleg fda data integr
breach cc et
issu statement investig
thought speak manag
 street outlook
pull consensu cc et
report revenu ebitda ep million million
sever move part ebitda came modestli us drive full-year contribut million
million consensu estim limit finish million net cash
million gross continu buy back stock expand million program
compani provid spend guidanc anticip sg rang million
million current forecast reflect continu platform build overal
pipelin updat remain key stock biggest updat around ryanodex eh
discuss manag healthcar confer link last week like get
question call morn
thought result void surpris still manag bring stock
spend move pipelin remain key hear anyth new follow confer last
week said clear data updat critic direct go forward
remain focu upcom investor meet manag
happen even freseniu announc conjunct full-year result
conduct independ investig use extern expert alleg breach fda data
integr requir relat product develop continu seek ftc clearanc
deal state clearli manag supervisori board assess find
consumm transact may affect close condit deal
met take mean find seen constitut mac-out scenario freseniu
could look break deal after-hour trade freseniu hold earn call
et tomorrow dial-in id freseniu expect main focu
put statement last night follow fre disclosur detail note
yesterday short releas fre comment three minor distinct
may over-read us thought worth call specif indic
work fre along outsid consult investig fre mention ii
point date compani investig found fact would result
materi impact oper mention fre iii indic believ
investig affect close transact fre fre point transact
may affect close condit merger agreement met
report revenu ep million come ahead consensu
million see varianc tabl compani continu execut well post target
first-tim guidanc introduct tend come light focu morn
revenu billion ebitda billion rang midpoint
street billion billion
titl link note
preliminari result come void surpris
delay call pend tax review cc
 colour investig fre call
addit thought
execut still tough spot
busi transform on-going chang view
post call manag
solid revenu outlook higher invest
announc preliminari adjust revenu billion impli revenu
billion rel consensu billion compani also announc postpon
final earn releas confer call previous schedul et morn
need addit time complet final incom tax review procedur relat certain non-cash item
timelin provid reschedul releas call also colour outlook provid
bit surpris bottom line probabl first impress new manag
includ new ceo uwe rohrhoff effect jan want provid street
got fre earn call began et end et manag provid
addit commentari follow last even disclosur investig alleg fda data
integr breach agre acquir last april billion provid
background disclos investig follow-up note morn issu statement
investig thought speak manag initi note last night deal
concern materi higher freseniu investig alleg fda data integr breach cc
provid frank assess us gener landscap recoveri earli need
cautiou sign stabil combin lower expect like
realist first-tim ebitda guid revers stock weak help set realist
expect compani move current headwind chang sector perform
depo report close result would normal focu given ebitda pressur
busi transit nucynta hand depo activ look transit
away pain specialty/cn transit earli thu far seen smart transact
need continu chang outlook
previou pre-announce rang remov print surpris revenu guid
solidli street greater spend pipelin launch off-set set
sustain growth boost oper leverag beyond look past guid focu shift
back pipelin capit alloc deliv updat reiter outperform
exhibit stock cover glenn novarro brandon henri
titl link note
guidanc leav room upsid
continu path top-line
growth om past
ww revenu line pre-announce ep line consensu ww revenu y/i
exclud fx organ organ growth acceler bp compar correspond growth rate
non-gaap ep within guidanc rang penni estim due higher
oper expens oper margin toward low end guidanc lower tax rate versu
assumpt guidanc contribut ep
report in-lin revenu ep beat driven partli higher incom report sale
rbce fce y/i constant currenc guidanc rbce includ revenu hit
hurrican maria in-line manag guidanc revenu growth rbce
revenu growth y/i rbce deliv adjust dilut ep exceed guidanc
fce higher incom drove ep beat adjust oper margin
rbce fce due lower sg ratio partial off-set y/i increas spend adjust
believ capit deploy potenti driver stock upsid near medium term addit
compani analyst meet may could provid potenti catalyst stock expect manag
provid deeper dive pipelin well long-term financi target
guidanc room upsid
attribut yesterday modest pullback still leav share year ep guid
despit lower tax rate rel updat howev case believ
guidanc revenu growth organ prove conserv drive higher ep rel guidanc
cynosur mammographi
tavr sale growth accur reflect underli demand also support recent tavr
survey howev disconnect report sale growth demand surfac certain quarter gener
creat better entri point continu recommend ew long-term core med-tech hold growth investor
prefer buy pullback
kick week tuesday expect manag provid guidanc cr bard mix report
tuesday dial-in access code back novemb provid guidanc without
bard howev cr bard deal close end thu anticip manag provid updat
guidanc current guidanc exclud bard call revenu guidanc report growth impli
revenu rbce ep rbce report earn
thursday februari market close report thursday pm dial-in access code
januari pre-announc revenu rbce vs fce increas
y/i constant currenc ep pre-announc howev manag guid adjust ep rbce
vs fce note four fewer sell day novemb manag issu guidanc
rbce vs fce y/i exclud fx
titl link note
strong finish year expect
high
large-cap med-tech stock buy
revenu guid soft ep
guidanc rais tax reform benefit
question
prior kick med-tech earn large-cap med-tech outperform moreov large-
cap med-tech trade forward estim compar year ago creat difficult set-up enter earn
season continu stock appreci compani need produc better-than-expect result issu strong
guid respect organ revenu growth margin expans ep growth compani deliv reward
handsom ew meanwhil compani perform line provid
conserv guid hit
report better-than-expect top-lin organ constant-curr result ep beat report
sale fce y/i organ constant-curr basi rbce sale y/i
rbce intern sale y/i constant currenc rbce report cash ep
fce y/i ep beat driven higher revenu lower tax rate rbce adjust
oper margin came line consensu adjust fce oper expens
ratio fce due higher sg ratio
ytd large-cap med-tech gain wipe away due recent market-wid sell-off spark attract entri
point mani stock large-cap coverag univers jan jan large-cap med-tech ralli howev
recent sell-off market wipe away major gain ytd large-cap med-tech flat lag
recent sell-off group believ creat attract entri point med-tech
investor large-cap med-tech current trade forward price-to-earnings jan slightli
three-year averag slightli report highlight three stock declin recent
valuat support limit downsid risk opinion ew
report solid start ep guidanc rais account benefit tax reform
partial off-set busi reinvest pt increas
retain bullish view medic suppli devic sector convict base three observ recent
channel check proprietari survey attend medic confer meet manag team support
belief end market cardio orthoped capit equip remain stabl respect volum price
saw strong ww ortho market base result strong cardio market af tavr base
result ew strong hospit admiss surgic volum base result
med-tech compani issu reason guidanc see mani sourc ep upsid includ share buy-back
fx front expect remain activ base commentari
manag team respect earn call attract entri point mani stock large-cap coverag
univers own recent market-wid sell-off recent sell-off med-tech trade slightli
titl link note
revenu earn growth show
sequenti improv
strong finish year adjust estim
revenu consensu ep in-lin
solid quarter lower estim buyer
pullback
guidanc set optimist tone
background recent japanes robot procedur reimburs recommend recal januari committe
ministri labour welfar mhlw japan recommend reimburs procedur da vinci
could use addit prostatectomi nephrectomi alreadi reimburs newli list procedur
categori includ surgeri mediastinum benign tumour surgeri lung cancer remov lung lobe one lung lobe
surgeri esophag cancer surgeri valvuloplasti gastrectomi fundectomi gastrectomi total gastric resect
proctectomi rectal amput surgeri bladder cancer surgeri uteru cancer estim categori
repres market opportun procedur japan
recommend buy share result due next tuesday new product easier comp drive
compar cc revenu growth next quarter new round cost save initi announc last month
keep compani track achiev long-term margin ep growth object consequ valuat discount
peer close reiter outperform price target
report revenu consensu revenu guidanc line consensu exclud adopt new
account standard topic lower revenu outlook price target reflect topic remain
one favourit small-cap pick
consolid result ww revenu y/i compar cc basi forecast
higher consensu currenc benefit report revenu vs estim benefit
four segment contribut upsid non-gaap oper margin lower estim vs rbce
due bigger neg fx impact exclud fx ebit margin non-gaap ep line
consensu rbce estim includ fx impact per prior guidanc report ep includ
world-wide spine market growth y/i y/i spine market y/i
versu y/i y/i continu suggest slower spine market may due
slower procedur growth consist recent spine survey manag believ y/i
procedur growth larg off-set y/i price declin separ intern spine market growth
y/i constant currenc saw rebound intern spine market growth vs larg flat
constant currenc revenu growth remain solid evidenc result segment-level guidanc
underli oper margin expans continu assum currenc volatil remain subdu
howev currenc higher tax rate lead lower ep lower ep tweak buyer
new leadership team achiev high degre success restor predict path revenu
growth cash flow gener de-lever consist margin improv still need attent guidanc
impli progress import metric maintain sector perform price target goe roll forward
base year valuat
extrem
monday
tuesday ktwo wednesday
kick week manag alreadi pre-announce provid revenu non-gaap oper margin
adjust ebitda guidanc pre-announce financi result expect manag updat ep
guidanc expect manag provid full guidanc focu lower extrem biolog
titl link note
expect revenu growth re-acceler throughout new product launch gain traction addit
debut surgic intellig platform nass septemb continu see valu share would
buyer recent pullback
result expect high
end previou guidanc
result slightli better januari pre-announc report revenu
previous announc vs rbce y/i organ basi vs manag initi guidanc
strong sale driven out-performance recent acquisit codman derma scienc improv
perform dural repair adjust ep higher consensu rbce vs fce manag
preliminari guidanc earli januari call adjust ep
afx continu struggl us nellix expect flat y/i ovat main driver growth
updat model reflect manag guidanc slightli consensu
adjust maintain sector perform rate introduc estim
revenu guidanc in-lin ebitda
see valu expect share move higher manag re-acceler growth lower
extrem busi howev potenti futur capit rais remain overhang
exhibit stock cover frank morgan
titl link note
attract near- long-term outlook
first quarter gate new ceo gail boudreaux post anoth solid perform
set strong outlook expect acceler earn growth come year
updat
solid near-term acceler long-term growth
take-away cmss advanc notic call net increas capit rate propos
enhanc part monitor protocol proven effect reduc opioid abus separ
believ cmss propos expand coverag daili mainten activ repres tailwind home health
compani especi given recent buildout person care platform across sub-sector
anoth solid perform manag segment deliv slight beat better-than-
expect outlook driven strong momentum across three busi segment
flu case increas approach decad
high seen
news nashvil
weekli perspect healthcar industri
extend bill look posit
instanc influenza-lik ill increas patient visit week flu season januari
chart page illustr accord cdc weekli influenza surveil report
nationwid week end januari week flu season patient visit due
influenza-lik ill ili prior week far exceed nation baselin level
note instanc ili bp peak level seen swine flu epidem
sector price perform week end februari healthcar servic stock outperform broader
market health servic select index spsihp declin versu declin
 strongest-perform subsector ambulatori surgeri flat perform
week acut care hospit declin versu gain prior week manag declin
versu gain prior week pharmaceut distribut weakest-perform subsector last week
take-away mandat budget neutral process give industri leader seat tabl
propos payment reform includ hous continu resolut bill look posit health provid
improv investor confid group repres improv current system
much better origin propos last year
ltac extend bill margin posit knd
despit site neutral cut impact
take-away extend bill contain cut site-neutr payment ltac see delay
implement site neutral payment slight posit knd see impact given
focu compliant patient
 solid finish year momentum
take-away humana inc nyse sp result exceed expect impress membership
growth annual enrol period compani carri solid momentum combin
product initi benefit tax cut job act posit consensu ep
guidanc increas dividend
titl link note
envis preview earn high end
guidanc
take-away evhc strong fourth quarter preview consist commentari earli januari
manag re-affirmed outlook strong result first two month quarter
margin concern overshadow result guidanc
flu case acceler reach
record ep drive ye momentum strong
take-away exit year solid momentum includ better-than-expect perform across
busi line strong membership growth individu group head said number
headwind margin side contribut earn growth long-term target rang along
concern return target margin led sell-off print
take-away result line consensu slightli ahead estim encourag
momentum experienc carri year-end compani see ramp perform
larg base newli acquir facil manag expect improv momentum combin
benefit tax reform led manag rais ep outlook consensu
instanc influenza-lik ill increas patient visit week flu season januari
chart follow page illustr accord cdc weekli influenza
surveil report nationwid week end februari week flu season
patient visit due influenza-lik ill ili prior week far exceed nation
baselin level note instanc ili reach decad high level par ili level seen
height swine flu epidem season
result reflect continu improv perform among recent acquir transit snf
strong momentum margin expans carri new year visibl oper perform
good combin benefit tax reform led higher ep guidanc pt
ytd gain wipe away see attract entri point mani stock univers
news nashvil
weekli perspect healthcar industri
back pure play
highlight week end februari sector price perform week end februari healthcar
servic stock outperform broader market health servic select index spsihp
declin versu drop strongest-perform subsector skill
nurs reflect solid perform well fluctuat genesi due
highli lever low-pric share acut care hospit declin versu declin prior week
manag declin versu declin prior week pharmaci benefit manag
weakest-perform subsector last week
take-away post decent perform continu oper close year solid
momentum dialysi volum remain stabl predict see encourag develop
legisl front time remain difficult predict sale dmg progress plan
compani continu direct strong cash flow toward de-lever signific repurchas well
potenti measur invest adjac healthcar busi outsid core dialysi care expertis
titl link note
solid line guidanc look strong
help tax rate
take-away close year strong ebitda line expect good perform
busi segment compani enter solid momentum manag initi guidanc call
margin expans hospic combin stabl perform roto-root benefit
tax reform led ep rang expect
tracker add feb aet
show strongest growth
strong perform segment
flu case may level downtick
week
news nashvil
weekli perspect healthcar industri
decent finish year guidanc look good
decent continu criteria recoveri
releas medicar advantag part enrol data februari ad member
roll sinc januari bring total enrol membership country-wid
increas sinc februari last year reflect increas penetr medicar advantag membership
among medicar elig popul year-to-d membership grown reflect larg bolu
new member join roll recent open enrol period medicar part enrol
uptick sequenti increas sinc februari last year
continu benefit solid top-line growth margin expans segment outlook
ep growth look attract conserv price target
instanc influenza-lik ill downtick patient visit week flu season
februari chart follow page illustr accord cdc weekli influenza
surveil report nationwid week end februari week flu season
patient visit due influenza-lik ill ili slightli prior week still far exceed
nation baselin level week downtick may suggest instanc ili peak decad
high level par ili level seen height swine flu epidem season
sector price perform week end februari healthcar servic stock under-perform broader
market health servic select index spsihp gain versu gain
 second straight week strongest-perform subsector skill nurs
larg due fluctuat genesi due highli lever low-pric share acut hospit gain
vs declin prior week manag uptick vs declin prior week
weakest perform subsector last week downtick
result slightli ahead expect consensu consist manag
revis guidanc given low expect go quarter think result guidanc
includ arrest near-term concern perform domest busi remain solid
decent top-line growth flat margin uk oper result similar anticip
issu impact uk perform like continu near term quick fix initi
guidanc bracket expect posit receiv bar
post solid result reflect higher expect revenu well margin expans specialti
hospit concentra partial off-set continu physiotherapi headwind outpati segment strong
specialti hospit perform includ solid admiss growth higher same-stor occup growth ltac
well solid contribut irf side complet acquisit financ
healthwork quarter re-affirmed initi guidanc given heavi flu season see strong
momentum
titl link note
flu case declin sharpli patient visit
week
okay guidanc frustrat
solid driven hospit concentra
segment nice set
news nashvil
weekli perspect healthcar industri
beat favour cost trend
fm post decent solid organ growth
larg off-set foreign exchang
instanc influenza-lik ill declin patient visit week flu season februari
chart follow page illustr accord cdc weekli influenza
surveil report nationwid week end februari week flu season
patient visit due influenza-lik ill ili bp prior week still far exceed
nation baselin level week rapid declin ili could suggest near end
sever flu season sinc swine flu epidem
friday reaction print guidanc reflect investor frustrat compani abil drive earn
growth despit final begin achiev margin expans portfolio recently-acquir hospit
lower pt reduc estim
consist manag lower expect outlook appear achiev
compani look sustain organ top-line growth slight margin expans address recent
perform challeng uk also capit bed expans need
post decent result solid perform ltac irf concentra segment though
physiotherapi acquisit short-term drag outlook affirm
sector price perform week end februari healthcar servic stock under-perform broader
market health servic select index spsihp lost versu gain
rehabilit strongest perform subsector last week gain acut
hospit declin vs gain prior week manag remain flat last week vs uptick
prior week senior live weakest perform subsector last week brookdal
announc conclud year-long strateg review result sale compani
hl post anoth solid quarter strong top-line growth segment includ notabl strong double-digit
organ volum growth health hospic segment fourth quarter adjust ebitda beat
expect solid top-line perform bolster lower group medic cost bad debt irf
side well continu product gain strong volum growth home health segment manag
affirm initi top-line ebitda ep guidanc rais outlook chang
close year posit note report consensu guidanc improv volum
includ encourag growth surgeri ed volum solid cost control improv backdrop
confid along earli result cost reduct initi manag increas outlook
fm post decent result adjust earn per american depositori share
bracket estim consensu reflect continu strong underli growth trend
includ higher bpci revenu partial off-set transit vascular access busi result reflect fm
averag eur usd rate impli averag rate approxim quarter
adjust result includ posit pre-tax adjust relat compani recent va agreement
exclud pre-tax cost relat natur disast quarter exclud legal charg
exclud defer tax balanc remeasur relat tax reform
titl link note
result line expect despit nois distract field
expect larg merger revis price target
unaccept offer end strateg review process lead new manag strategi combat industri
headwind quick fix share like range-bound lower rate sector perform
price target
noisi quarter ebitda guidanc line
result noisi outlook appear bracket consensu ebitda
slight miss guidanc slightli
rebound guidanc
despit solid growth across busi line result guidanc slightli street expect
evhc provid clean modest beat recent updat guidanc importantli manag
feel highli confid visibl newli issu guidanc first bottom-up model sinc
merger built unifi management team noth report strateg review process amr remain
track close provid de-lever
exhibit stock cover brian abraham
titl link note
progress cf competit
greater screen posit
set stage ocaliva growth
better-than-expect uptak baricitinib europ vs estimate regulatori
pathway remain track highlight potenti emerg jak inhibitor class continu believ
filgotinib highli competit efficaci safeti profil could enabl strong entrant ultim ww
sale potenti especi rheumatolog field shift toward small molecul time like adcomm bari
come month could shed import light regulatori percept class safeti
new studi publish yesterday jama psychiatri analyz nearli uk women decad shed new
light neg impact moderate/sever post-partum depress long-term welfar children-
 make power case increas awar screen treatment believ studi conjunct
near-term avail brexanolon potenti later effect treat disord
prompt increas public health initi ultim broaden diagnos beyond half pt
current identifi widen market opportun revenu potenti asset indic
continu believ share undervalu transform role neurosteroid medicin could
treatment neuropsychiatr disord
fda updat ocaliva label new label avail view one favour
potenti scenario box warn cite hepat failur risk child-pugh b/c pt incorrectli dose
drug caution dose weekli mention later label monitor liver function pt pbc
diseas progress decompens notabl label even hedg whether drug even truli caus
liver post-market report cite insuffici inform rule confound factor role
patient underli diseas make emphasi risk milder pt see remov major
overhang stock believ label hand abl effect re-engag
physician re-ignit ocaliva uptak help drive share appreci year nash data
past two day broader market correct see particularli opportun entri point among sever
larg mid small-cap biotechnolog name within coverag univers
highlight top-read differenti piec januari provid updat view
feedback highlight includ upgrad celg bd commentari avxs/biib sma competition/safeti link
note found appendix
major threat epti
morn report top-lin data ubrogep oral cgrp inhibitor acut treatment
migrain treatment competit
eptinezumab long-term migrain prevent import readthrough potenti
competit oral cgrp prophylact atogep came away remain confid mab like epti like
cleaner especi liver safeti addit discuss call regard enthusiasm space
botox oral highlight larg market opportun enabl room multipl player --
valu believ substanti underappreci aldr share current level
titl link note
turn page hcv bic launch
near pipelin matur
tysabri fail stroke impact given
close donut hole potenti
implic senat budget deal
differenti sight initi outperform
gener in-lin quarter higher-than-consensu hiv sale help boost overal revenu catalyz
ep beat notabl news guidanc competit dynam plu market
shrinkag expect reduc hcv sale though believ lower expect
opex guidanc come slightli higher-than-expect level overal street begin look beyond
hcv expect come believ stage remain set near-term earn nadir visibl
toward growth driven hiv car-t pipelin
hcv guidanc wash expect higher-than-expect project opex patent cliff make
like trough nonetheless matur pipelin potenti blockbust strong hiv fundament growth
like enhanc bictegravir launch substanti oncolog prospect like out-year margin expans see
increas visibl toward lt growth appreci potenti stori set next chapter adjust
target
tysabri failur stroke morn like limit impact sens expect
quit low though believ increasingli cite potenti call option catalyst might drive
enthusiasm mid-stag pipelin continu believ mid-stag neuro pipelin scientif
sound gener interest program reach later stage take time matur
meantim expect share trade line balanc low commerci risk lt pipelin option
biktarvi approv clean label though expect come sever day pdufa help
set stage long-term growth sustain core hiv franchis estimate peak sale
continu momentum share earli approv help perpetu posit sentiment growth
note budget deal come senat includ provis increas amount
manufactur must pay medicar recipi part coverag gap current overal
see limit impact individu compani estim gener next ten year
seem rel low-hang fruit senat seek pay-for senat budget deal would
initi outperform rate price target believ valuat underappreci likelihood
approv lead drug schizophrenia market opportun across variou psychiatr
indic would buyer upcom regulatori interact potenti launch
high royalti stem mavyret launch highlight hcv competit strength proprietari pipelin
remain promis though potenti de-risk data nash/pbc rsv like least year
away increas price target reflect favour hcv dynam believ provid
titl link note
past sever month discuss extens possibl gsk/viiv initi lawsuit
potenti bictegravir patent infring broad dolutegravir ip inde expect follow
yesterday biktarvi approv taken place overal see low stock impact issu
identifi previous come onto investor radar preliminari injunct block biktarvi launch
extrem unlik think good likelihood ultim prevail worst case would like
single-digit royalti gsk/viiv
share pre-market morn report ep vantag confirm dose
temporarili halt uk site compani on-going ph iii studi golodirsen casimersen next-gen
exon-skip drug dmd
previous discuss report temporari dose stoppag ph iii essenc studi golodirsen
casimersen dmd see note speak compani morn remain comfort
unlik major issu program would use weak buy opportun
risk return political/headlin drug price debat one bearish concern
biotech sector see appear return earnest white paper issu white
hous council econom advis morn lay specif goal reform biopharma price though
propos allud recent day around budget discuss concept
new detail convey interest believ somewhat measur approach toward control
drug spend acknowledg import innov -- biopharma industri -- economi
polici may broadli increment unfavour drug maker
implement big unknown today sell-off may knee-jerk reaction re-emerg drug price
headlin follow several-quart hiatu post-elect overal tone consist thesi pressur
real like gradual modest rather draconian see reason panic noth
new contain far balanc drug price worri contemplated-
think biotech fundament still sound still see mani compel valu especi recent market
note announc initi ph iii revers nash trial patient compens cirrhosi
line prior guidanc trial initi follow label updat end quarter
fda approv tez/iva brand symdeko slightli earli in-lin label homozyg residu
popul broadli expect overal posit provid near-term growth driver set anoth
build block continu develop improv cf combo long-term leadership slight list price premium
orkambi interest increment favour revenu opportun view recent share price soft
unwarr remain buyer strong fundament top- bottom-lin growth margin expans
titl link note
fda label updat add hypersensit
cite observ case rash urticaria pyrexia flush cough dyspnea bronchospasm hypotens fda
updat exondi label today make caregiv awar potenti hypersensit reaction see
meaning impact term uptak use pattern patient retent label chang remain
posit share
afternoon announc mrk bace
inhibitor verubecestat discontinu
ph iii studi prodrom alzheim diseas
patient entir surpris given
disappoint prior data believ
expect class inc
afternoon announc mrk bace inhibitor verubecestat discontinu ph iii studi
prodrom alzheim diseas patient entir surpris given disappoint prior data believ
expect class includ biib/eisai-partn elenbecestat low highlight inher
risk unknown alzheim diseas develop though mechan entir applic biib
aducanumab current level believ share alreadi appropri balanc reward/risk
program show add proof concept
opportun spend time senior manag team follow continu believ
mavyret establish strong posit hcv treatment paradigm fxr rsv program
potenti best-in-class attribut follow recent run-up limit clinic data catalyst
believ share may like trade line though posit progress proprietari pipelin could
announc mid-day today due variabl observ primari cdr-sb endpoint
expand ph iii aducanumab studi patient maintain power spoke
re-affirmed analysi done blind data note similar re-pow done
ph iii tecfidera ms studi ultim success disclos whether futil analysi
also includ pre-specified analysi whether addit interim look take place this/next year
timelin chang due low dropout faster expect enrol remain track
complet enrol summer fact studi continu histor situat
studi success follow re-pow likelihood studi stoppag interim later year
might lower increment posit net-net view neg highlight inher
challeng alzheim studi risk outcom upon long-term growth highli depend
morn announc posit result phase ii studi treatment acut pain
though pain space challeng believ benefit look fairli compel signific unmet
need new non-opioid base therapi complet clear whether plan partner out-lic
continu develop intern still program like matur manifest d/bd
effort beyond cf abil gener out-year growth opportun cf matur becom
recogn see addit appreci potenti
announc line quarter sale meet expect compani work toward
rebound pbc growth doc re-educ well execut nash studi regener interim
continu believ current stock price contain littl nash expect appreci next year data
pbc scrip potenti grow solidifi valuat floor
titl link note
given mani question receiv sinc reveal increas size aducanumab ph iii
maintain power due variabl consult statistician attempt clarifi chang
mean see modestli increas risk adu studi follow updat outcom less binari
stock level note increas import bd lt growth
full data present morn posit ph ii studi otezla ulcer coliti uc reaffirm view
high likelihood futur success drug potenti expand signific ibd market
rel low risk view otezla uc one mani pipelin program street overlook could
potenti provid growth diversif celg revenu stream year continu believ
celg share substanti under-valued
remain critic like baricitinib adcomm provid read likelihood approv
contribut valuat floor critic epacadostat ph iii melanoma data set potenti signific
upsid opportun continu like reward/risk stock level adjust tgt model
recently-issu guidanc develop treatment dmd relat dystrophinopathi fda
appear clearli support use dystrophin express surrog endpoint potenti acceler
approv dmd drug see increas likelihood fda consid golodirsen potenti
casimersen acceler approv key upcom updat regulatori feedback market-
expand exon-skip oligo later quarter like favour drive stock upsid
somewhat unanticip turn event success invalid idenix patent own district
court prior juri trial result damag would like also includ futur on-going
royalti remov probability-adjust damag charg futur royalti would result
upsid prior price target thu rais price target
weekend aad glpg present fuller data morphosys-partn antibodi atop
dermat recal top-lin data report septemb overal though ph ib small detail
provid believ data lend support potenti activ differenti current
avail therapi may take time discern note posit progress antibodi would lead
upsid valuat remain focus divers glpg non-cf asset
interest earli though see reward/risk fairli balanc glpg current share price
morn fda provid feedback anoth dmd compani deni appeal
prior ataluren complet respons letter expect notabl recommend collect dystrophin data
possibl path acceler approv drug see posit read-through believ
reinforc fda support highlight agenc dmd guidanc last week discuss use
dystrophin express surrog acceler approv dmd drug
surpris upsid idenix damag revers
posit read-through golo approv path
fda feedback dmd co
titl link note
morn announc fda reiter previou posit deni appeal
ataluren/translarna nda decis larg expect alter valuat includ
valu sale translarna model interestingli fda leav door open indic potenti
path forward base quantif chang dystrophin protein use newer technolog item like
collect logist assay methodolog would still need sort better understand potenti viabil
path overal view increment posit
unanim non-preferenti
recommend heplisav-b
morn acip advisori committe immun practic cdc vote support posit
recommend heplisav-b hbv vaccin adult consid preferenti statu hbv
machin upend
upsid market opportun data catalyst
even market close announc start first tripl combo ph iii studi
potenti allow file pt combo look gener line compani prior
messag base case scenario reflect regulatori flexibl somewhat rapid path
high-unmet need het/min cf popul see high po expect tripl combo build current
grow cf domin remain buyer share given vrtx strong fundament top- bottom-lin
growth margin expans competit posit
morn announc collabor sangamo line recent express interest gene
edit technolog includ yesterday hc confer reinforc view substanti addit
invest enhanc car-t enabl compani cellular therapi platform evolv substanti
revenu gener long-term remain buyer
limit new news key program track brexanolon commerci readi continu nda file
multipl trial depression/sleep disord remain tap nmda platform matur new
depress treatment concept still requir regulatori buy-in overal continu believ aggress
innov clinic approach could disrupt potenti revolution multipl neuropsych treatment paradigm
multi- sale opportun reflect valuat
glpg provid increment updat regard favour belgian tax reform slightli higher-than-expect
guidanc opex primarili relat increas filgotinib expens pivot trial progress
posit expect filgotinib note decreas emphasi cf attent increas glpg
promis pipelin program like though remain sidelin data matur earlier-
look toward near-term launch cgrp mab gaug potenti price market size could
yield upsid street conserv estim aldr number data catalyst
bla file come recent hc confer migrain panel believ iv opportun
ph iii long-term extens studi second-gen corrector tez/iva het/min cf tripl combo
post clinicaltri gov design alreadi disclos compani last week
see anyth notabl term detail inclusion/exclus criteria list new
timelin studi
titl link note
afternoon celg announc fda issu refuse-to-fil letter nda ozanimod multipl sclerosi
cite defici nonclin clinic pharmacolog section
execut program deliveri
bcrx program progress well trial plan shift execut manag march toward
deal close remain commit lay rational bcrx/idra merger set
optim prospect ultim success pt unchang reiter outperform rate given
favour view benefit/risk
celg announc receipt refus file letter fda ms drug ozanimod increment
posit view though sens ozanimod still good likelihood ultim reach
market like delay potenti import oral competitor tecfidera within ms franchis
appear weather one key competit entrant space ocrevu reason well alreadi
sens ozanimod rtf like reflect major issu profil would prevent ultim
approv increas risk push timelin competit area adjust chang tgt
still like celg best-in-class nt growth pipelin breadth though good news sore need restor
investor confid abil diversifi around revlimid
continu progress clinic addit pt enrol pivot type sma trial
strong type trial compani also expand pipelin offer first glimps preclin als/rett
program look toward pre-bla meet expect later year addit clariti path
forward adjust price target model adjust
exhibit stock cover kennen mackay
titl link note
earn qualiti like
focu
see slight top-lin miss rare-bottom line miss base-busi product drive quarterli perform
see potenti increas concern surround earn qualiti mix perform growth driver
financi engin finest buyback tax
king dead long live king azn
lynparza beat zejula top parpi
gu abstract continu support cabo
posit tki
download focu remain hl adcetri
approv pipelin diversifi
world updat add kanuma valu lal-
transfer price mechan larg offset base busi headwind quarter base busi threat remain
focu legal decis sensipar pediatr exclus patent expiri esa competit launch
neulasta biosimilar time off-set posit capit alloc action
azn financi post anoth quarter strong us lynparza growth us sale q/q
tsro zejula guidanc morn azn financi show lynparza us sale
q/q well ahead st estim consecut quarter strong us lynparza sale
growth follow august approv broad mainten ovarian cancer set
takeaway today market close gu abstract releas provid increment updat cabo
cabosun rcc result cabo nivo /-ipi combo result sub-group analysi cabosun saw cabo
favour across key patient sub-group idmc risk statu presenc bone met vs sutent sunitinib view
data solidifi cabo posit tki choic rcc see ipi nivo regimen choic
rcc though given benefit combo restrict tumor minor patient
continu like cabo opportun first-lin tki choic combin cabo nivo /-ipi also appear
compel evid synergist efficaci could enabl cabo co-exist io futur rcc
rapidli diversifi late stage pipelin though focu remain adcetri grow us drug
adcetri q/q growth opportun guidanc impli limit demand growth ex-pric
take current market increas focu may pdufa updat model reflect sale
expens guidanc us tax reform maintain price target
takeaway present long-term data kanuma vital studi poster photo attach
infant rapidli progress lal-d updat confirm kanuma strong valu proposit lal-d patient
mark increas surviv vs natur histori howev note largest hindranc kanuma growth
remain patient identif provid confirm kanuma benefit valu proposit
anticip sale inflect point expect share meaning impact data
focu foundat bullish stanc remain pnh top-lin data
potenti data demonstr meaning benefit pnh patient vs soliri
titl link note
anticip palisad studi succeed base experi patient
characterist compar trial within peanut allergi field forecast potenti disrupt/grow
peanut allergi desensit market reach peak unadjust global sale
dupix see continu strong us growth sni
eu launch lag vs street est
dupix us revenu indic solid perform ex-u uptak slow start vs street estim
morn sanofi report us ex-u dupix revenu assum per sni
financi us sale came line estimate street show strong q/q
growth eu sale came street expect dupix gain market share
country-by-countri basi eu us dupi sale come impli im script see
preview fluctuat q/q captur rate inventori discrep continu complic exact
forecast view us result indic continu solid uptak dupix q/q growth continu
impress
day proof concept
appear nail mps-iiib dose first shot promis biomark reduct clean safeti
day follow-up patient treat
wed world mp iiib updat
takeaway today provid updat compani studi assess intracerebroventricular icv
administ enzym replac therapi ert mp iiib last seen oct day
biomark data continu look strong cerebrospin fluid heparan sulfat csf hf normal
dose-escal cohort sustain transit observ studi dose-expans
cohort qw dose also saw rapid sustain csf hf normal also shown new
safeti concern treatment discontinu date meanwhil liver volum normal indic
good pk lead peripher activ somat organ howev initi brain ventricular
volum reduct mix albeit earli cognit dq also yet show consist stabil though
anticip longer treatment durat requir biomark benefit translat
clinical/outcom benefit await futur updat better gaug dynam remain
upsid valuat
assum coverag outperform specul
risk price target
like lead candid mirvetuximab fr-posit ovarian cancer ahead plan near-term futil
analysi program combo data
assum coverag outperform specul
risk price target
assum coverag like stock first-of-a-kind launch gene therapi luxturna
addit pipelin inflect point provid catalyst-rich year view share attract current level
surpris beat guidanc
soliri post unexpect beat though sale guidanc come expectedli light report
revenu unexpectedli beat estim estim see ep
preview note particular soliri revenu came beat st estim estim
non-gaap ep vs estim estim metabol
franchis show strensiq kanuma post see world symposia kanuma
titl link note
dme data compel though
check box yet
pnh updat indic new surpris
plan come focu
point share sold today updat mps-iiia high neurocognit variabl
seen view buy opportun variabl observ cohort importantli
variabl driven singl outlier present dr kevin flanigan note singl poorer perform
sick test administ could contribut poor perform
neurocognit analysi view st misinterpret result particularli attend view
pullback buy opportun
continu like data see high likelihood demonstr benefit vs
soliri soliri guidanc came light vs expect view take clear backseat data
year dictat futur growth trajectori compani
weekend asco-gu result combin cabo opdivo doublet cabo opdivo yervoy
triplet genitourinari tumor urothelia carcinoma uc renal cell carcinoma rcc present view
initi result highli compel doubl key efficaci paramet orr rcc vs current
treatment option entri io agent rcc ad competit tki entri opdivo rcc
like near-term approv opdivo yervoy rcc pdufa april convers
physician suggest io agent rapidli becom prefer regimen howev given biolog orthogon
resist mechan view decreas durat tki sequenc behind io agent
continu view cabo market intact tki choic data cabo meteor trial even suggest potenti
increas durat post-io see potenti io cabo combo regimen grow long-term posit rcc
via part futur soc doublet triplet tki io regimen
roch present result boulevard studi assess compani bispecif
diabet macular edema dme patient angiogenesi confer initi data compel
higher dose show sign bcva anatom improv howev caveat
studi compar vs roch lucenti oppos eylea shown superior vs
lucenti dme long-term time frame particularli sever baselin visual acuiti
wors nonetheless see result ad competit headwind eylea long-term market
posit await futur follow-up data better assess long-term durabl efficaci safeti
takeaway morn rarx announc complet dose addit result trial assess
sc paroxysm nocturn hemoglobinuria pnh updat larg line previou
report dec show compel efficaci soliris-na transfusion-independ switch
patient inadequ respond cohort also saw addit patient pool analysi
patient transfusion-independ switch patient show promis ldh hemoglobin stabil howev
opportun transfusion-depend soliri patient whether switch inadequ respond remain
question given breakthrough hemolysi signal seen date patient rarx management plan move forward
sq daili dose select like focu treatment-na transfusion-
independ switch patient benefit seen await full present result management
guidanc regard path forward fda meet plan continu maintain transfusion-
depend switch inadequ respond upsid valuat see previou note
titl link note
vadadustat program updat enhanc
abstract void efficacy/safeti data
rai-dtc ist show poc await trial
design includ rai-dtc model
quick take morn provid updat vadadustat variou program notabl enrol
target design updat trial
spoke management indic intent behind updat
develop/broaden vadadustat commerci posit key real-world switch scenario updat
assess once-daili three-times-weekli vadadustat dose vs short-act epogen long-act aranesp
mircera esa vs long-act previous enabl show in-lin potenti superior efficaci trial
power show non-inferior vs full breadth current soc option long-act esa gain traction
though per earn short-act epogen still command compani total ckd-relat
anemia sale epogen vs aranesp updat also assess once-daili three-
times-weekli vadadustat dose expand target broader popul beyond hypo-respond
management indic us trial serv public strategi better outlin vadadustat valu
proposit real-world use highlight variou angl vadadustat could effect compet
esa soc safeti conveni efficaci across broader patient popul
quick take morn announc result palisad studi present aaaai
march abstract late-break post see though note safety/efficaci data
avail therefor await top-lin pr due feb present full result march
et better gaug dynam
recent ist demonstr proof concept metastat radioiodin rai -refractori differenti thyroid
carcinoma dtc orr came soc lenvima though durabl could differenti mpf reach
vs lenvima mpf rai-dtc could significantli expand current approv mtc indic
thyroid cancer present dtc vs mtc rai-dtc case per year vs current approv
dbv bla unsurpris view
weak buy oppi palisad
competitor dbv trade european market follow disclosur fda support file
